Insilico Announces Preclinical Candidate for Inhalable Formulation of Generative AI IPF Drug

📣 Announcing the preclinical candidate for an inhalation solution of ISM001-055, the first anti-fibrotic small molecule inhibitor developed leveraging Insilico's proprietary AI drug discovery platform Pharma.AI for the treatment of the chronic progressive lung disease Idiopathic Pulmonary Fibrosis (IPF).
● With promising preclinical results, Insilico is proceeding with IND filing as the first AI drug discovery company to venture into nebulized formulations.
● Potential advantages for the inhalation solution include a smaller effective dose, larger safety window, and reduced side effects.
● As demonstrated in preclinical studies, the inhalation solution of ISM001-055 is well tolerated with good anti-fibrotic and anti-inflammatory efficacy, favorable safety and pharmacokinetic (PK) profiles, and no local or systemic toxicity observed.
Learn more: www.eurekalert.org/news-relea...

[@merlynraber3308]

When will the new dug be available?

[@AbellLincoln]

God Gave Noah the Rainbow Sign
No More Water but Fire Next Time
🌈🙏🔥📡🌎🎶💥🤵👰❤️‍🔥🤴👸